QualityStocks'  Instablog

Mobile video sharing company Thwapr announced it has signed an exclusive agreement with Shyalala, a leading marketing and branding company in Asia, to develop new business opportunities by introducing Thwapr as a new Asian visual communication channel through which brands and personalities can engage their communities.

Delivering end-to-end marketing and branding solutions for multi-national companies, award-winning agency Shyalala has worked with such brands as Pepsi, Esprit, Calvin Klein, BHP Billiton, and ExxonMobil and has rolled out campaigns in Singapore, Hong Kong, Beijing, and Shanghai. Through the partnership, Shyalala will work closely with Thwapr in delivering a strategy for building community engagement services using Thwapr's proprietary mobile video sharing technology. Shyalala will additionally leverage its business relationships and alliances to integrate Thwapr as part of its current offering. Thwapr will provide technical support and the resources needed to service the Asia Pacific marketplace.

Marketers in Asia sell mobile as an integral extension of traditional brand marketing techniques; furthermore, Asia will continue dominating the global mobile advertising space with an anticipated 33.6% share of the $20.6 billion mobile ad revenue forecasted for 2015. Shyalala projects that the next growth market will be creating a perpetual mobile community for brands to deliver and share mobile video. Through the partnership with Shyalala, Thwapr will be positioned to fill a void in Asia in delivering solutions to marketers for a broad variety of mobile devices - not just smartphones.

Thwapr, a mobile video sharing platform company, has engineered a proprietary technology to deliver optimum mobile video quality and the best possible user experience regardless of a user's device, network, or carrier. The company's seamless, device-indifferent process enables users to socialize video content and provides a solution for monetizing the mobile community. Thwapr was founded by digital video pioneers from Apple, Avid, and MTV, and the company's patent-pending technology provides brands and marketers with a new visual communication channel to engage hundreds of millions of consumers with Web-enabled mobile devices.

For more information, visit the company's Web site at thwapr.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

FluoroPharma, a developer of specialized molecular imaging pharmaceuticals used with positron emission tomography (PET) to help detect heart disease and other problems, has stated that it intends to develop its products through the completion of phase II and/or phase III studies, at which point it will seek to partner with organizations that may facilitate the further development and distribution of its products.

Phase I clinical trials have already been completed on the company's two lead products, CardioPET and BFPET, with pre-clinical trials completed for VasoPET, all related to cardiovascular disease (CAD) detection. The company's AZPET product for detecting amyloid deposits in the brain for Alzheimer's disease evaluation is currently in the development stage. Over 12 million patients in the U.S. alone have some degree of acute or chronic CAD, and millions of patients undergo molecular imaging studies every year, often to detect and evaluate such heart disease.

Assuming CardioPET and BFPET are approved, their competition will be the current standard of care, and companies that are engaged in the development and commercialization of novel cardiac perfusion agents. However, FluoroPharma says it does not see competition coming from specific competitors for CardioPET and to some degree for BFPET. FluoroPharma's technologies will be competing mainly on an indication-by-indication basis with the existing or coming standards of care.

FluoroPharma believes current experimental imaging agents are limited by their short half-lives (generally less than ½ hour), requiring faster image collection and/or an on-site cyclotron or generator to provide an additional supply. For this reason, they believe that these agents represent little or no potential competition to FluoroPharma products. In contrast, the imaging agent used in FluoroPharma products has a 110-minute half-life, and is more amenable to regional production and distribution to off-site nuclear medicine centers.

For more information, see the company website at FluoroPharma.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Medical device maker InspireMD said this morning that it has completed enrollment in its MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial testing its stent platform technology for use in patients with Acute Myocardial Infarctions. The completion of enrollment has been achieved one month ahead of schedule, according to the company.

The MASTER Trial is a multinational randomized controlled trial being conducted in 50 centers across nine countries (Germany, Hungary, Israel, Poland, Czech Republic, France, Ireland, Brazil, and South Africa) designed to evaluate the MGuard™ and MGuard Prime Coronary Stents compared with the standard of care, bare metal stents (BMS), or drug eluting stents (DES) for acute ST-elevation myocardial infarction (STEMI) patients. The trial has enrolled 432 patients in a two-arm, parallel design study.

The primary endpoint is complete ST segment resolution. Clinical follow-up will continue for one year and important secondary endpoints such as TIMI (Thrombolysis In Myocardial Infarction) flow, MBG (Myocardial Blush Grade) and MACE (Major Adverse Cardiac Events) will be measured. Sub-studies include infarct size measured by cardiac MRI, as well as restenosis by invasive angiographic follow-up at 13 months.

The company is on track to release preliminary top line results in the third quarter of 2012.

One week ago, the InspireMD reported positive three-year results from the extended follow-up MAGICAL trial, a prospective, single arm, multi-center study conducted in 2008-09 that enrolled 60 STEMI patients, at a company-sponsored symposium at the EuroPCR conference in Paris. In that report, the company detailed that the safety and efficacy of MGuard™ observed in the trial were maintained for three years.

Shares of the Tel Aviv, Israel-based healthcare company are continuing to search for a bottom. Trading near $3 one year ago, share value has slipped as low as 60 cents recently. A modest rise occurred in early trading today, with shares climbing 7.14% to 75 cents on today's news.

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net